Anticancer Platinum Drugs Update
Acknowledgments
Conflicts of Interest
References
- Rosenberg, B. Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften 1973, 60, 399–406. [Google Scholar] [CrossRef] [PubMed]
- Rosenberg, B.H.; Vancamp, L.; Trosko, J.E.; Mansour, V.H. Platinum Compounds: A New Class of Potent Antitumour Agents. Nat. Cell Biol. 1969, 222, 385–386. [Google Scholar] [CrossRef] [PubMed]
- Rosenberg, B.; Vancamp, L. The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res. 1970, 30, 1799–1802. [Google Scholar] [PubMed]
- Einhorn, L.H. Curing metastatic testicular cancer. Proc. Natl. Acad. Sci. USA 2002, 99, 4592–4595. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Varbanov, H.P.; Kuttler, F.; Banfi, D.; Turcatti, G.; Dyson, P.J. Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis. PLoS ONE 2019, 14, e0211268. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oun, R.; Moussa, Y.E.; Wheate, N.J. The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Trans. 2018, 47, 6645–6653. [Google Scholar] [CrossRef] [PubMed]
- Rottenberg, S.; Disler, C.; Perego, P. The rediscovery of platinum-based cancer therapy. Nat. Rev. Cancer 2021, 21, 37–50. [Google Scholar] [CrossRef] [PubMed]
- Hato, S.V.; Khong, A.; de Vries, J.; Lesterhuis, W.J. Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics. Clin. Cancer Res. 2014, 20, 2831–2837. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rébé, C.; Demontoux, L.; Pilot, T.; Ghiringhelli, F. Platinum Derivatives Effects on Anticancer Immune Response. Biomolecules 2019, 10, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Frenzel, D.; Köppen, C.; Bauer, O.B.; Karst, U.; Schröter, R.; Tzvetkov, M.V.; Ciarimboli, G. Effects of Single Nucleotide Polymorphism Ala270Ser (rs316019) on the Function and Regulation of hOCT2. Biomolecules 2019, 9, 578. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ciarimboli, G.; Ludwig, T.; Lang, D.; Pavenstädt, H.; Koepsell, H.; Piechota, H.; Piechota, H.-J.; Haier, J.; Jaehde, U.; Zisowsky, J.; et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005, 167, 1477–1484. [Google Scholar] [CrossRef] [Green Version]
- Ciarimboli, G.; Deuster, D.; Knief, A.; Sperling, M.; Holtkamp, M.; Edemir, B.; Pavenstädt, H.; Lanvers-Kaminsky, C.; Zehnhoff-Dinnesen, A.A.; Schinkel, A.H.; et al. Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective Interventions. Am. J. Pathol. 2010, 176, 1169–1180. [Google Scholar] [CrossRef] [PubMed]
- Sprowl, J.A.; Ciarimboli, G.; Lancaster, C.S.; Giovinazzo, H.; Gibson, A.A.; Du, G.; Janke, L.J.; Cavaletti, G.; Shields, A.F.; Sparreboom, A. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc. Natl. Acad. Sci. USA 2013, 110, 11199–11204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lanvers-Kaminsky, C.; A Sprowl, J.; Malath, I.; Deuster, D.; Eveslage, M.; Schlatter, E.; Mathijssen, R.H.; Boos, J.; Jürgens, H.; Zehnhoff-Dinnesen, A.G.A.; et al. Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics 2015, 16, 323–332. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Antonaci, G.; Cossa, L.G.; Muscella, A.; Vetrugno, C.; De Pascali, S.A.; Fanizzi, F.P.; Marsigliante, S. [Pt(O,O′-acac)(γ-acac)(DMS)] Induces Autophagy in Caki-1 Renal Cancer Cells. Biomolecules 2019, 9, 92. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nejad, M.A.; Urbassek, H.M. Adsorption and Diffusion of Cisplatin Molecules in Nanoporous Materials: A Molecular Dynamics Study. Biomolecules 2019, 9, 204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nguyen, D.H.; Bach, L.G.; Nguyen Tran, D.-H.; Cao, V.D.; Nguyen, T.N.Q.; Le, T.T.H.; Tran, T.T.; Thi, T.T.H. Partial Surface Modification of Low Generation Polyamidoamine Dendrimers: Gaining Insight into their Potential for Improved Carboplatin Delivery. Biomolecules 2019, 9, 214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ciarimboli, G. Anticancer Platinum Drugs Update. Biomolecules 2021, 11, 1637. https://doi.org/10.3390/biom11111637
Ciarimboli G. Anticancer Platinum Drugs Update. Biomolecules. 2021; 11(11):1637. https://doi.org/10.3390/biom11111637
Chicago/Turabian StyleCiarimboli, Giuliano. 2021. "Anticancer Platinum Drugs Update" Biomolecules 11, no. 11: 1637. https://doi.org/10.3390/biom11111637